白物质高强度组织属性空间变化作为帕金森病认知状态的函数
Mariyemuguli Reheman1, Sagar Buch2, Naying He1
1Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Er Road, Shanghai 200025, China.
NeuroImage
|April 25, 2025
概括
在帕金森病 (PD) 中,白质过强度 (WMH) 与认知能力下降有关. 它们的位置和组织特性,而不仅仅是体积,显著影响PD患者的认知障碍.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 生物医学工程 生物医学工程
背景情况:
- 帕金森病 (PD) 与认知障碍有关.
- 白质过强度 (WMH) 在与PD相关的认知衰退中的作用尚未完全理解.
- 之前的研究在评估WMH位置和组织特性方面存在局限性.
研究的目的:
- 研究WMH负担,空间分布和组织特性与帕金森病的认知障碍之间的关系.
- 使用T2-FLAIR和定量MRI (qMRI) 进行详细的WMH评估.
- 阐明WMH特征对PD认知衰退的具体贡献.
主要方法:
- 招募了122名PD患者和65名健康对照 (HC).
- 根据认知状态分组PD患者 (正常,MCI,PDD) 使用MoCA得分.
- 分析了WMH体积,空间分布 (热图,周周直径距离) 和qMRI测量 (含水量,T1,T2*).
- 进行了克尔智能分析,将WMH组织特性与MoCA得分相关联.
主要成果:
- 在患有痴呆症的PD (PDD) 中,WMH体积更高,与MoCA得分负相关.
- WMH主要是周周结膜性,后部角参与是PDD特有的.
- qMRI测量结果显示,与正常白质相比,WMH的显著变化.
- 周心室WMH组织特性与认知状态有很强的相关性.
结论:
- WMH的空间分布和组织特性是PD认知障碍的关键因素,不仅仅是体积.
- 不同的WMH模式与PD的不同认知阶段有关.
- 定量核磁共振 (MRI) 提供了关于将WMH与PD认知衰退联系起来的病理机制的宝贵见解.
更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
39.7K
09:33Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
Published on: July 28, 2013
28.1K
相关概念视频
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Parkinson's Disease: Overview
319
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
319
